Agoracom: Small Cap Investment - Zenith Epigenetics - Zenith Presentation at AACR Meeting April 10-15

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Zenith Presentation at AACR Meeting April 10-15

posted on Apr 09, 2021 02:43PM

AACR Annual Meeting: April 10-15, 2021

1129 - Combination of ZEN-3694 with talazoparib is a novel therapeutic approach in ER positive breast cancer resistant to CDK4/6 inhibitors, independent of BRCA status

https://www.abstractsonline.com/pp8/#!/9325/presentation/2286

4 Recommendations

Re: Zenith Presentation at AACR Meeting April 10-15

Toinv

Apr 11, 2021 11:30AM

Re: Zenith Presentation at AACR Meeting April 10-15

fuzzyjr

Apr 11, 2021 02:24PM

Re: Zenith Presentation at AACR Meeting April 10-15

KayakerBC

Apr 12, 2021 09:09AM

Re: Zenith Presentation at AACR Meeting April 10-15